UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): April 19, 2021

 

 

QSAM BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   000-55148   20-1602779
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification Number)

 

9442 Capital of Texas Hwy N, Plaza 1, Suite 500

Austin, Texas

  78759
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code   (512) 343-4558

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company [X]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

 

 

 
 

 

Item 8.01 Other Items

 

On April 19, 2021, the Company issued a letter to shareholders / press release relating to accomplishments in 2020, future milestones, and explanations of certain items in the Company’s Form 10-K filed on April 15, 2021. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in Exhibit 99.1 is being furnished and such information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ( the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as may be expressly set forth by specific reference in such a filing/

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number   Description
99.1   Press release issued on April 19, 2021

 

 
 

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  QSAM Biosciences, Inc.
   
  By: /s/ Christopher Nelson
    Christopher Nelson
    General Counsel
     
    Date: April 20, 2021

 

 

 

QSAM BioSciences (QB) (USOTC:QSAM)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more QSAM BioSciences (QB) Charts.
QSAM BioSciences (QB) (USOTC:QSAM)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more QSAM BioSciences (QB) Charts.